Mitralign

Mitralign, Inc. was a Tewksbury, Massachusetts-based medical device company that developed transcatheter valve repair technologies to treat functional mitral and tricuspid regurgitation. The company's flagship technology was a direct transcatheter annuloplasty system designed to reduce annular size through tissue plication, enabling minimally invasive, percutaneous procedures for cardiac valve repair without open-heart surgery. Mitralign's Trialign system was used for transcatheter repair of tricuspid valve regurgitation, while its percutaneous annuloplasty system targeted functional mitral regurgitation. In 2019, Edwards Lifesciences acquired certain assets of Mitralign, including intellectual property and associated clinical and regulatory experience.